Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.

Palvella Therapeutics Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Adicet Bio (ACET – Research Report), Palvella Therap...

Analysts Are Bullish on Top Healthcare Stocks: Adicet Bio (ACET), Palvella Therapeutics (PVLA)

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Palvella Therapeutics today and set a price target of $130.00. Slutsky covers the He...

Current Quarter	$-0.95	Next Quarter	$-0.87
Current Year	$-3.46	Next Year	$-3.61
QoQ Growth	+8.4%	YoY Growth	-4.3%
3Y EPS CAGR	-122.6%	Target Price	$127.67
Consensus	Buy	Upside	+29.5%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PVLA	$98.58	+1.86%	189.13K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PVLA	$98.58	+1.9%	189.13K
3
4
5
6

PVLA

PVLA

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Palvella Therapeutics Inc. Data in Excel

Get Palvella Therapeutics Inc. Data in Excel